Skip to Content
Merck
All Photos(1)

Key Documents

C0465000

Carbimazole

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

2,3-Dihydro-3-methyl-2-thioxo-1H-imidazole-1-carboxylic acid ethyl ester

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C7H10N2O2S
CAS Number:
22232-54-8
Molecular Weight:
186.23
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

carbimazole

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C7H10N2O2S/c1-3-11-7(10)9-5-4-8(2)6(9)12/h4-5H,3H2,1-2H3

InChI key

CFOYWRHIYXMDOT-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Carbimazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Adoree Yi Ying Lim et al.
Singapore medical journal, 54(7), e133-e136 (2013-08-01)
A 24-year-old Chinese woman with Graves' disease presented with myositis two months after treatment with carbimazole. The patient's myositis resolved with hydration and cessation of carbimazole. No other causes of myositis were found, and a change in the medication to
[59 year-old man with skin and eye alterations and diabetes mellitus].
N Ewald et al.
Deutsche medizinische Wochenschrift (1946), 137(19), 997-998 (2012-05-03)
Kirsten Campbell et al.
Australian family physician, 41(8), 564-572 (2012-11-13)
Thyrotoxicosis is common in the Australian community and is frequently encountered in general practice. Graves disease, toxic multinodular goitre, toxic adenoma and thyroiditis account for most presentations of thyrotoxicosis. This article outlines the clinical presentation and evaluation of a patient
Matteo Cassina et al.
Birth defects research. Part A, Clinical and molecular teratology, 94(8), 612-619 (2012-04-19)
Clinical hyperthyroidism has been associated with an increased risk of maternal, fetal, and neonatal complications. The available antithyroid drugs are methimazole/carbimazole and propylthiouracil. Several case reports and some epidemiologic studies suggest that methimazole/carbimazole exposure during the first trimester of pregnancy
Maternal thyrotoxicosis and fetal goitre requiring in utero therapy for hypothyroidism and subsequent neonatal therapy for hyperthyroidism.
Katie Groom et al.
Journal of paediatrics and child health, 49(1), E102-E103 (2013-01-17)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service